Compare Abeona Therapeutics Inc (ABEO) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs FedEx Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while FedEx Corporation trades at $323.98 (market cap $76.28B). The key difference: FedEx Corporation is far larger — about 181.1× Abeona Therapeutics Inc's market cap, and FedEx Corporation pays a 1.51% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FDX | |
|---|---|---|
Market Cap | $421.19M | $76.28B |
Sector | Health | Industrials |
52-Week High | $7.45 | $338.75 |
52-Week Low | $4.17 | $180.51 |
Enterprise Value | $276.10M | $105.91B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
FedEx (FDX) trades at $325.08, up 2.04% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $360.27 highlight positive momentum. The company's network transformation and focus on premium shipments are driving operational improvements, though revenue has been flat year-over-year. Cash flow trends show a projected rebound in 2026, with net cash flow turning positive.
The outlook for FDX is favorable, supported by cost-cutting initiatives and strategic shifts toward high-margin business. Key risks include competitive pressures and macroeconomic sensitivity. With 57% of analysts rating it a buy and institutional interest growing, the stock presents a compelling opportunity for growth-oriented investors, albeit with exposure to economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
